See more : Hi-Tech Pipes Limited (HITECH.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Ampio Pharmaceuticals, Inc. (AMPE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ampio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Encore Energy Systems, Inc. (ENCS) Income Statement Analysis – Financial Results
- Synchrony Financial (SYF-PB) Income Statement Analysis – Financial Results
- Hokkaido Gas Co., Ltd. (9534.T) Income Statement Analysis – Financial Results
- Beyond, Inc. (BYON) Income Statement Analysis – Financial Results
- Maxscend Microelectronics Company Limited (300782.SZ) Income Statement Analysis – Financial Results
Ampio Pharmaceuticals, Inc. (AMPE)
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 76.79K | 50.00K | 50.00K | 18.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 250.00K | 2.08M | 1.09M | 1.18M | 1.27M | 523.00K | 568.00K | 950.00K | 369.31K | 2.24M | 1.74M | 1.45M | 0.00 | 0.00 | 0.00 | 950.00 | 0.00 | 0.00 |
| Gross Profit | -250.00K | -2.08M | -1.09M | -1.18M | -1.27M | -523.00K | -568.00K | -950.00K | 793.15K | -2.16M | -1.69M | -1.40M | 18.75K | 0.00 | 0.00 | -950.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 68.23% | -2,818.46% | -3,376.00% | -2,798.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.44M | 8.92M | 11.90M | 9.17M | 12.62M | 6.83M | 10.42M | 10.55M | 18.96M | 26.92M | 18.29M | 7.49M | 6.65M | 1.97M | 1.07M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Other Expenses | 0.00 | 1.94M | 0.00 | 12.00K | 56.00K | 0.00 | 323.55K | 143.80K | 0.00 | 0.00 | 0.00 | 0.00 | 34.01K | 0.00 | 0.00 | 950.00 | 1.20K | 0.00 |
| Operating Expenses | 9.27M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.10M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Cost & Expenses | 9.52M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.46M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Interest Income | 348.00K | 220.00K | 4.00K | 12.00K | 77.00K | 5.00K | 3.09K | 23.48K | 59.85K | 22.26K | 12.29K | 21.94K | 6.68K | 815.00 | 1.09K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.36K | 19.55K | 4.18K | 2.65K | 0.00 | 0.00 |
| Depreciation & Amortization | 127.00K | 2.08M | 1.09M | 1.18M | 1.27M | 1.28M | 1.21M | 1.21M | 1.14M | 439.10K | 137.68K | 62.40K | 42.55K | 815.00 | 0.00 | 0.00 | 2.19K | 0.00 |
| EBITDA | 0.00 | -18.30M | 0.00 | 0.00 | -17.30M | 35.26M | -14.46M | -14.81M | -23.34M | 0.00 | -23.89M | -11.76M | -11.08M | -8.01M | -21.87K | -29.23K | -26.81K | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,760.35% | -50,310.73% | -47,747.81% | -23,472.97% | -59,119.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.52M | -24.21M | -25.16M | -15.22M | -23.45M | -11.18M | -15.56M | -17.08M | -33.30M | -39.07M | -24.02M | -11.82M | -11.13M | -6.70M | -21.87K | -29.23K | -29.00K | -1.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,864.79% | -50,882.57% | -48,047.74% | -23,641.65% | -59,382.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 886.00K | 4.05M | 3.50M | -60.00K | 4.95M | 45.17M | -36.22M | -2.08M | -412.07K | -7.60M | -504.16K | 227.29K | -7.14M | -1.35M | -4.18K | -2.65K | -2.19K | 0.00 |
| Income Before Tax | -8.63M | -16.34M | -17.08M | -15.89M | -13.63M | 33.99M | -51.89M | -19.16M | -33.71M | -39.05M | -24.53M | -11.59M | -18.28M | -8.05M | -26.05K | -31.88K | -31.20K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,900.24% | -50,853.58% | -49,056.85% | -23,186.23% | -97,475.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.87M | -4.59M | 604.00K | -4.95M | 45.17M | 36.33M | 1.04M | -1.29M | -923.52K | -519.87K | -68.00 | 82.50K | 18.73K | 0.00 | 0.00 | 800.00 | 1.00K |
| Net Income | -8.63M | -8.47M | -12.49M | -16.50M | -8.68M | 33.99M | -51.89M | -19.16M | -32.01M | -38.13M | -24.01M | -11.59M | -18.36M | -8.05M | -26.05K | -31.88K | -32.00K | -1.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,753.66% | -49,650.87% | -48,017.12% | -23,186.09% | -97,915.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -10.67 | -11.24 | -18.79 | -28.63 | -18.32 | 92.10 | -239.13 | -107.06 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| EPS Diluted | -10.66 | -11.24 | -18.59 | -27.71 | -18.32 | 91.90 | -238.41 | -106.91 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| Weighted Avg Shares Out | 809.00K | 753.62K | 664.33K | 576.16K | 474.03K | 369.00K | 217.00K | 179.00K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
| Weighted Avg Shares Out (Dil) | 810.11K | 753.62K | 671.49K | 595.41K | 474.03K | 369.81K | 217.66K | 179.24K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update
ENGLEWOOD, Colo., April 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter...
Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects
ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that...
Ampio Pharmaceuticals' Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis
ENGLEWOOD, Colo., April 6, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the results of a pre-clinical study demonstrating that Ampion inhibits an important...
Ampio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory Issues
Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, presented March 24, 2021 at the Benzinga Biotech Small Cap Conference. By Mark Gilman
Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress
ENGLEWOOD, Colo., March 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the company will present its findings on a poster entitled,...
Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion in COVID-19 Respiratory Distress
ENGLEWOOD, Colo., March 16, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, recently revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion...
Ampio Pharmaceuticals to Participate in the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
ENGLEWOOD, Colo., March 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it has been invited to participate in the 33rd Annual ROTH Growth Conference being...
Why Ampio Pharmaceuticals Stock Is Jumping Today
Investors liked what they heard in the company's Q4 update.
Ampio Pharmaceuticals' (AMPE) CEO Mike Macaluso on Q4 2020 Results - Earnings Call Transcript
Ampio Pharmaceuticals' (AMPE) CEO Mike Macaluso on Q4 2020 Results - Earnings Call Transcript
Ampio Pharmaceuticals, Inc. to Report Annual 2020 Financial Results and Provide Corporate Business Update
ENGLEWOOD, Colo., Feb. 24, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss the financial...
Source: https://incomestatements.info
Category: Stock Reports